GridAI Technologies (GRDX) Receivables - Other (2015 - 2025)

GridAI Technologies' (GRDX) quarterly Receivables - Other came in at $1.3 million in Q4 2025, up 6645.26% on a QoQ basis from -$20000.0 in Q2 2023.

GridAI Technologies (GRDX) Receivables - Other (2015 - 2025) Analysis & Trends

GridAI Technologies (GRDX) has 10 years of Receivables - Other data on file, last reported at $1.3 million in Q4 2025.

Quarterly Receivables - Other changed N/A year-over-year to $1.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.3 million (changed N/A YoY) and the FY2025 annual result came in at $1.3 million, changed N/A from the prior year.
Receivables - Other rose to $1.3 million in Q4 2025, from -$20000.0 in the prior quarter.
In the past five years, Receivables - Other ranged from a high of $1.3 million in Q4 2025 to a low of -$98970.0 in Q4 2022.
A 4-year average of $171010.4 and a median of $35214.5 in 2022 frame the typical range for Receivables - Other.
Annual changes were most pronounced in 2021 — Receivables - Other jumped 102.86% — and 2023, when it plunged 360.25%.
Tracing GRDX's Receivables - Other over 4 years: stood at $59030.0 in 2021, then tumbled by 267.66% to -$98970.0 in 2022, then soared by 79.79% to -$20000.0 in 2023, then surged by 6645.26% to $1.3 million in 2025.
The last three Receivables - Other figures came in at $1.3 million (Q4 2025), -$20000.0 (Q2 2023), and -$73014.0 (Q1 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.71 Bn	131.86 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.55 Bn	78.55 Bn	3.93 Bn
3	Argenx Se	65.26 Bn	60.07 Bn	1.37 Bn
4	Moderna	59.81 Bn	54.67 Bn	52.00 Mn
5	BeOne Medicines	42.16 Bn	37.06 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.87 Bn	28.56 Bn	992.69 Mn
7	BioNTech SE	28.13 Bn	9.74 Bn	668.28 Mn
8	Insmed	27.53 Bn	26.37 Bn	358.27 Mn
9	Royalty Pharma	27.31 Bn	26.47 Bn	-
10	GridAI Technologies	5.95 Mn	5.95 Mn	-

Download Data